Metabolic diseases encompass various disorders resulting in physiological and biochemical imbalances, affecting various organs, including the liver, pancreas, and adipose tissue, leading to the development of several health complications such as diabetes, diabetic complications, obesity, and NASH. Syngene’s expertise in preclinical animal models for metabolic diseases can provide valuable insights into the efficacy and safety of potential therapeutic interventions. We specialize in various chemical, genetic, and diet-induced in vivo pharmacology efficacy models for metabolic diseases.
Categories:
- Diabetes and obesity
- Diabetes complications
- Germfree mice capabilities
- Humanized liver model
- NASH
For the list of validated animal models, download the PDF
